克隆氏症(CD)治疗的全球市场

克隆氏症(CD)治疗的全球市场，2030年将达到159亿美元

在COVID-19后改变的商务环境中，2022年109亿美元的克隆氏症(CD)治疗的全球市场，2030年之前达到159亿美元，在2022年到2030年间预计将以表示年复合成长率4.9％的速度成长率。本报告所分析之市场区隔之一的抗肿瘤坏死因子生技药品年复合成长率将记录5.8％，到分析期间结束时将达到67亿美元。考虑疫情后的復苏，胺基水杨酸盐分野地的成长，今后8年的年复合成长率被2.8％。

美国市场估算为32亿美元，中国以年复合成长率4.5％增长

美国的克隆氏症(CD)治疗市场在2022年估算为32亿美元。作为世界第2大经济大国的中国，在2022年到2030年间年复合成长率预计将为4.5％，2030年将达到28亿美元的市场规模。其他热门的地区市场有日本和加拿大，在2022年到2030年间预计将各以4.8％和3.7％的速度成长。在欧洲市场中，德国以年复合成长率3.8％成长。

调查对像企业范例

• AbbVie, Inc.
• Amgen, Inc.
• AstraZeneca PLC
• Biogen, Inc.
• Boehringer Ingelheim International GmbH
• Celltrion Healthcare Co., Ltd.
• ChemoCentryx, Inc.
• Ferring Pharmaceuticals
• Johnson & Johnson
• Merck & Co., Inc.
• Mitsubishi Tanabe Pharma Corporation
• Novartis AG
• Novo Nordisk A/S
• Pfizer, Inc.
• Takeda Pharmaceutical Co., Ltd.
• UCB SA

目录

第1章 调查手法

第2章 摘要整理

• 市场概要
• 主要企业
• 市场趋势与推动因素
• 全球市场预测

第3章 市场分析

• 美国
• 加拿大
• 日本
• 中国
• 欧洲
• 法国
• 德国
• 义大利
• 英国
• 其他欧洲
• 亚太地区
• 全球其他地区

第4章 竞争

What`s New for 2023?

»Special coverage on Russia-Ukraine war; global inflation; easing of "zero-Covid" policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.

»Global competitiveness and key competitor percentage market shares

» Market presence across multiple geographies - Strong/Active/Niche/Trivial

»Online interactive peer-to-peer collaborative bespoke updates

»Access to our digital archives and MarketGlass Research Platform

»Complimentary updates for one year

Looking Ahead to 2023

The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet. Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China's already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

Global Crohn`s Disease (CD) Therapy Market to Reach $15.9 Billion by 2030

In the changed post COVID-19 business landscape, the global market for Crohn`s Disease (CD) Therapy estimated at US$10.9 Billion in the year 2022, is projected to reach a revised size of US$15.9 Billion by 2030, growing at aCAGR of 4.9% over the period 2022-2030. Anti-TNF Biologics, one of the segments analyzed in the report, is projected to record 5.8% CAGR and reach US$6.7 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Aminosalicyates segment is readjusted to a revised 2.8% CAGR for the next 8-year period.

The U.S. Market is Estimated at $3.2 Billion, While China is Forecast to Grow at 4.5% CAGR

The Crohn`s Disease (CD) Therapy market in the U.S. is estimated at US$3.2 Billion in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$2.8 Billion by the year 2030 trailing a CAGR of 4.5% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.8% and 3.7% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 3.8% CAGR.

Select Competitors (Total 46 Featured) -

• AbbVie, Inc.
• Amgen, Inc.
• AstraZeneca PLC
• Biogen, Inc.
• Boehringer Ingelheim International GmbH
• Celltrion Healthcare Co., Ltd.
• ChemoCentryx, Inc.
• Ferring Pharmaceuticals
• Johnson & Johnson
• Merck & Co., Inc.
• Mitsubishi Tanabe Pharma Corporation
• Novartis AG
• Novo Nordisk A/S
• Pfizer, Inc.
• Takeda Pharmaceutical Co., Ltd.
• UCB SA

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • Crohn`s Disease (CD) Therapy - Global Key Competitors Percentage Market Share in 2022 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
  • Impact of Covid-19 and a Looming Global Recession
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Recent Past, Current & Future Analysis for Crohn`s Disease (CD) Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • TABLE 2: World Historic Review for Crohn`s Disease (CD) Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • TABLE 3: World 16-Year Perspective for Crohn`s Disease (CD) Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2023 & 2030
  • TABLE 4: World Recent Past, Current & Future Analysis for Aminosalicyates by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • TABLE 5: World Historic Review for Aminosalicyates by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • TABLE 6: World 16-Year Perspective for Aminosalicyates by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
  • TABLE 7: World Recent Past, Current & Future Analysis for Immunomodulators by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • TABLE 8: World Historic Review for Immunomodulators by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • TABLE 9: World 16-Year Perspective for Immunomodulators by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
  • TABLE 10: World Recent Past, Current & Future Analysis for Anti-TNF Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • TABLE 11: World Historic Review for Anti-TNF Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • TABLE 12: World 16-Year Perspective for Anti-TNF Biologics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
  • TABLE 13: World Recent Past, Current & Future Analysis for Anti-Integrin Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • TABLE 14: World Historic Review for Anti-Integrin Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • TABLE 15: World 16-Year Perspective for Anti-Integrin Biologics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
  • TABLE 16: World Recent Past, Current & Future Analysis for Biosimilars by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • TABLE 17: World Historic Review for Biosimilars by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • TABLE 18: World 16-Year Perspective for Biosimilars by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
  • TABLE 19: World Recent Past, Current & Future Analysis for Other Segments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • TABLE 20: World Historic Review for Other Segments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • TABLE 21: World 16-Year Perspective for Other Segments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
  • TABLE 22: World Crohn`s Disease (CD) Therapy Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Crohn`s Disease (CD) Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
  • TABLE 23: USA Recent Past, Current & Future Analysis for Crohn`s Disease (CD) Therapy by Segment - Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • TABLE 24: USA Historic Review for Crohn`s Disease (CD) Therapy by Segment - Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • TABLE 25: USA 16-Year Perspective for Crohn`s Disease (CD) Therapy by Segment - Percentage Breakdown of Value Sales for Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments for the Years 2014, 2023 & 2030
• CANADA
  • TABLE 26: Canada Recent Past, Current & Future Analysis for Crohn`s Disease (CD) Therapy by Segment - Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • TABLE 27: Canada Historic Review for Crohn`s Disease (CD) Therapy by Segment - Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • TABLE 28: Canada 16-Year Perspective for Crohn`s Disease (CD) Therapy by Segment - Percentage Breakdown of Value Sales for Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments for the Years 2014, 2023 & 2030
• JAPAN
  • Crohn`s Disease (CD) Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
  • TABLE 29: Japan Recent Past, Current & Future Analysis for Crohn`s Disease (CD) Therapy by Segment - Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • TABLE 30: Japan Historic Review for Crohn`s Disease (CD) Therapy by Segment - Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • TABLE 31: Japan 16-Year Perspective for Crohn`s Disease (CD) Therapy by Segment - Percentage Breakdown of Value Sales for Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments for the Years 2014, 2023 & 2030
• CHINA
  • Crohn`s Disease (CD) Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
  • TABLE 32: China Recent Past, Current & Future Analysis for Crohn`s Disease (CD) Therapy by Segment - Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • TABLE 33: China Historic Review for Crohn`s Disease (CD) Therapy by Segment - Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • TABLE 34: China 16-Year Perspective for Crohn`s Disease (CD) Therapy by Segment - Percentage Breakdown of Value Sales for Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments for the Years 2014, 2023 & 2030
• EUROPE
  • Crohn`s Disease (CD) Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
  • TABLE 35: Europe Recent Past, Current & Future Analysis for Crohn`s Disease (CD) Therapy by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • TABLE 36: Europe Historic Review for Crohn`s Disease (CD) Therapy by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • TABLE 37: Europe 16-Year Perspective for Crohn`s Disease (CD) Therapy by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2023 & 2030
  • TABLE 38: Europe Recent Past, Current & Future Analysis for Crohn`s Disease (CD) Therapy by Segment - Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • TABLE 39: Europe Historic Review for Crohn`s Disease (CD) Therapy by Segment - Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • TABLE 40: Europe 16-Year Perspective for Crohn`s Disease (CD) Therapy by Segment - Percentage Breakdown of Value Sales for Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments for the Years 2014, 2023 & 2030
• FRANCE
  • Crohn`s Disease (CD) Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
  • TABLE 41: France Recent Past, Current & Future Analysis for Crohn`s Disease (CD) Therapy by Segment - Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • TABLE 42: France Historic Review for Crohn`s Disease (CD) Therapy by Segment - Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • TABLE 43: France 16-Year Perspective for Crohn`s Disease (CD) Therapy by Segment - Percentage Breakdown of Value Sales for Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments for the Years 2014, 2023 & 2030
• GERMANY
  • Crohn`s Disease (CD) Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
  • TABLE 44: Germany Recent Past, Current & Future Analysis for Crohn`s Disease (CD) Therapy by Segment - Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • TABLE 45: Germany Historic Review for Crohn`s Disease (CD) Therapy by Segment - Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • TABLE 46: Germany 16-Year Perspective for Crohn`s Disease (CD) Therapy by Segment - Percentage Breakdown of Value Sales for Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments for the Years 2014, 2023 & 2030
• ITALY
  • TABLE 47: Italy Recent Past, Current & Future Analysis for Crohn`s Disease (CD) Therapy by Segment - Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • TABLE 48: Italy Historic Review for Crohn`s Disease (CD) Therapy by Segment - Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • TABLE 49: Italy 16-Year Perspective for Crohn`s Disease (CD) Therapy by Segment - Percentage Breakdown of Value Sales for Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments for the Years 2014, 2023 & 2030
• UNITED KINGDOM
  • Crohn`s Disease (CD) Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
  • TABLE 50: UK Recent Past, Current & Future Analysis for Crohn`s Disease (CD) Therapy by Segment - Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • TABLE 51: UK Historic Review for Crohn`s Disease (CD) Therapy by Segment - Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • TABLE 52: UK 16-Year Perspective for Crohn`s Disease (CD) Therapy by Segment - Percentage Breakdown of Value Sales for Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments for the Years 2014, 2023 & 2030
• REST OF EUROPE
  • TABLE 53: Rest of Europe Recent Past, Current & Future Analysis for Crohn`s Disease (CD) Therapy by Segment - Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • TABLE 54: Rest of Europe Historic Review for Crohn`s Disease (CD) Therapy by Segment - Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • TABLE 55: Rest of Europe 16-Year Perspective for Crohn`s Disease (CD) Therapy by Segment - Percentage Breakdown of Value Sales for Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments for the Years 2014, 2023 & 2030
• ASIA-PACIFIC
  • Crohn`s Disease (CD) Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
  • TABLE 56: Asia-Pacific Recent Past, Current & Future Analysis for Crohn`s Disease (CD) Therapy by Segment - Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • TABLE 57: Asia-Pacific Historic Review for Crohn`s Disease (CD) Therapy by Segment - Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • TABLE 58: Asia-Pacific 16-Year Perspective for Crohn`s Disease (CD) Therapy by Segment - Percentage Breakdown of Value Sales for Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments for the Years 2014, 2023 & 2030
• REST OF WORLD
  • TABLE 59: Rest of World Recent Past, Current & Future Analysis for Crohn`s Disease (CD) Therapy by Segment - Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • TABLE 60: Rest of World Historic Review for Crohn`s Disease (CD) Therapy by Segment - Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • TABLE 61: Rest of World 16-Year Perspective for Crohn`s Disease (CD) Therapy by Segment - Percentage Breakdown of Value Sales for Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments for the Years 2014, 2023 & 2030

IV. COMPETITION